Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06458075 · ClinicalTrials.gov registry record · NA

Intervention to Improve Communication and Medication Adherence in Lupus

A NA study of Systemic Lupus Erythematosus, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
480
Enrollment target
1
Study location

NCT06458075: Recruiting NA study of Systemic Lupus Erythematosus, sponsored by Duke University.

NCT06458075 is a NA study of Systemic Lupus Erythematosus that is actively recruiting participants, run by Duke University. The registered enrollment target is 480 participants, above the 376-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (28% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06458075, a NA study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
480 participants
Enrollment target
1
Study location

Study Summary

CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE). The purpose of this study is to optimize the culturally appropriate delivery and test the effect of the CO-LEAD intervention, which includes the following: 1. clinicians will be provided with a program to teach them to use effective communication strategies with patients to review real-time pharmacy refill date, engage and formulate solutions to adherence barriers, and collaboratively overcome adherence barriers. 2. use of a reliable and valid patient-reported measure of the extent of and reasons for nonadherence that helps patients identify and communicate their adherence barriers with clinicians proactively, efficiently, and comprehensively.

Primary Outcome

Proportion of SLE patient visits in which a nonjudgmental, patient-centered adherence discussion took place as determined by analysis of clinic visit audio recordings

Interventions

  • BEHAVIORAL CO-LEAD

Study Locations (1)

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2024-07-01
Est. Completion 2028-12
Phase NA
Duke University

1,725 total trials

What NCT06458075 shows while recruiting

NCT06458075 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 376-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (28% higher).

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which CO-LEAD is the first listed.

NCT06458075 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT06458075 about?

NCT06458075 is a clinical study titled "Intervention to Improve Communication and Medication Adherence in Lupus". CO-LEAD is an intervention to improve patient-provider communication and medication adherence among patients with systemic lupus erythematosus (SLE). The purpose of this study is to optimize the culturally appropriate delivery and test the effect of the CO-LEAD intervention, which includes the foll...

What is the current status of trial NCT06458075?

This trial is currently recruiting. It is a NA study. The enrollment target is 480 participants. The study started on 2024-07-01. Estimated completion is 2028-12.

What conditions does trial NCT06458075 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT06458075?

The interventions under investigation include: CO-LEAD (BEHAVIORAL).

Who is sponsoring clinical trial NCT06458075?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06458075 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06458075's enrollment target sits among peer trials

480 17th of 99 higher than 83 of 99 other Systemic Lupus Erythematosus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01954992 · 480 participants · Phase 3

    Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

  • NCT03023696 · 480 participants · NA

    Can Prophylactic Foraminotomy Prevent C5 Palsy

  • NCT04948060 · 480 participants · NA

    Tribally Engaged Approaches to Lung Screening (TEALS)

  • NCT05053230 · 480 participants · NA

    A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06458075, the US trial registry maintained by the National Library of Medicine. NCT06458075 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.